Skip to main content
OXFORD BIODYNAMICS PLC logo

OXFORD BIODYNAMICS PLC — Investor Relations & Filings

Ticker · OBD ISIN · GB00BD5H8572 LEI · 2138005Y1TK258O5U928 IL Professional, scientific and technical activities
Open in API
Filings indexed 416 across all filing types
Latest filing 2022-03-30 AGM Information
Country GB United Kingdom
Listing IL OBD

About OXFORD BIODYNAMICS PLC

https://www.oxfordbiodynamics.com/

Oxford BioDynamics PLC is a global biotechnology company advancing personalized healthcare by developing and commercializing precision medicine tests. The company's proprietary EpiSwitch® platform utilizes 3D genomics and epigenetic biomarkers to create diagnostic solutions for life-changing diseases, with a focus on oncology. Its portfolio of clinical tests includes the EpiSwitch® PSE, a blood test that assesses the likelihood of prostate cancer with high accuracy to help reduce unnecessary biopsies, and the EpiSwitch® CiRT, a test designed to predict a patient's therapeutic response to Immune Checkpoint Inhibitor cancer therapies. The platform enables the translation of 3D genome regulation into clinical applications for precision medicine at scale.

Recent filings

Filing Released Lang Actions
Results of Annual General Meeting
AGM Information Classification · 98% confidence The document explicitly states 'Results of Annual General Meeting' and confirms that 'all resolutions at the Company's Annual General Meeting, held earlier today, were duly passed.' This directly corresponds to the definition of AGM Information (AGM-R). Although it is a regulatory filing (indicated by the RNS Number and LSE footer), the specific content is about the AGM results, making AGM-R the most precise classification over the general RNS or RPA.
2022-03-30 English
Group of companies' accounts made up to 2021-09-30
Regulatory Filings
2022-03-16 English
PDMR Dealing
Director's Dealing Classification · 100% confidence The document is identified by the RNS Number header and the presence of the RNS distribution tracking image/link, indicating it is a regulatory news service announcement from the London Stock Exchange. The content explicitly details a 'PDMR Dealing' (Persons Discharging Managerial Responsibilities) transaction, specifically the acquisition of Ordinary Shares by the CEO, Dr. Jon Burrows. This type of insider transaction disclosure, mandated by UK Market Abuse Regulation, falls under the category of Director's Dealing (DIRS). Although it is a regulatory filing, DIRS is a more specific and appropriate classification than the general RNS fallback.
2022-03-04 English
PDMR Dealing
Director's Dealing Classification · 100% confidence The document starts with an 'RNS Number' and is dated '03 March 2022'. The content details a 'PDMR Dealing' (Persons Discharging Managerial Responsibilities) transaction involving a Non-Executive Director, Stephen Diggle, and the subsequent notification required under UK Market Abuse Regulation. This type of insider transaction reporting, especially when issued via RNS (the news service of the London Stock Exchange), directly corresponds to the definition of Director's Dealing (DIRS). Although it is an RNS announcement, the specific content is highly indicative of DIRS, which takes precedence over the general RNS fallback.
2022-03-03 English
PUBLICATION OF 2021 ANNUAL REPORT
Report Publication Announcement Classification · 99% confidence The document explicitly states: "PUBLICATION OF 2021 ANNUAL REPORT" and further clarifies that copies of the "annual report and accounts for the year ended 30 September 2021 (incorporating the Notice of Annual General Meeting) ("Annual Report") have been posted to shareholders." Although the content is about the Annual Report (10-K), the document itself is a short announcement stating that the report has been published and is available elsewhere (website/posted to shareholders). According to Rule 2 (The 'MENU VS MEAL' Rule), a short announcement about the publication of a report should be classified as a Report Publication Announcement (RPA). The RNS Number and the closing statement confirm this is a regulatory announcement format.
2022-03-01 English
US launch of EpiSwitch® CiRT for oncology
Regulatory Filings Classification · 100% confidence The document begins with 'RNS Number : 7966C' and contains contact information referencing 'RNS, the news service of the London Stock Exchange' and the 'Financial Conduct Authority'. This strongly indicates a regulatory announcement disseminated via the RNS system. The content itself is an announcement about the US launch of a specific product (EpiSwitch® CiRT) by Oxford BioDynamics PLC, detailing its features, validation, and market availability. This type of broad, immediate corporate news release that doesn't fit neatly into specific financial reporting categories (like 10-K, ER, or DIV) is best classified as a general Regulatory Filing or Announcement, which corresponds to the RNS code.
2022-02-25 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.